Junesoo Jeon

Junesoo Jeon

Auto-generated profile, based on publicly available information

Junesoo Jeon

Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JJJunesoo Jeon
Junesoo Jeon
YCYun-Sun Choi
Yun-Sun Choi
YKYejin Kim
Yejin Kim
SHSiryeon Hong
Siryeon Hong
JSJi-Hee Sung
Ji-Hee Sung
CRCheong-Rae Roh
Cheong-Rae Roh
Abnormal vaginal colonisation can lead to adverse pregnancy outcomes such as preterm birth through intra-amniotic inflammation. Despite the concern, little is known about its risk factors and impact in pregnant women at high-risk for spontaneous preterm birth. Thus, we conducted this single-centre retrospective cohort study including 1381 consecutive women who were admitted to the high-risk pregnancy unit. The results of vaginal culture at admission were categorised according to the colonising organism: bacteria (Gram-negative or -positive) and genital mycoplasmas. Maternal baseline socioeconomic, and clinical characteristics, as well as pregnancy, delivery, and neonatal outcomes were compared according to the category. Maternal risk factors for Gram-negative colonisation included advanced maternal age, increased pre-pregnancy BMI, a greater number of past spontaneous abortions, earlier gestational age at admission, and IVF. Gram-positive colonisation was likewise associated with earlier gestational age at admission. Genital mycoplasmal colonisation was associated with a greater number of past induced abortions, a lower level of education completed, and a lower rate of multifetal pregnancy and IVF. The neonates from mothers with Gram-negative colonisation had a greater risk of NICU admission, proven early onset neonatal sepsis, and mortality. However, not Gram-positive bacteria or genital mycoplasma was directly associated with adverse pregnancy outcomes.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
YLYeonju Lee
Yeonju Lee
JJJunesoo Jeon
Junesoo Jeon
SOSe Jin Oh
Se Jin Oh
JPJihye Park
Jihye Park
HPHye Jung Park
Hye Jung Park
JLJong Hee Lee
Jong Hee Lee
Background: TRTP‐101 is a novel regenerative therapy consisting of autologous adipose‐derived mesenchymal stem cells (ADMSCs) formed into three‐dimensional (3D) microtissues (microblocks, MiBs). The living 3D MiBs are designed to be extracellular matrix–enriched and organoid/tissue‐like, supporting sustained trophic signaling following intradermal delivery for atrophic scars. Objectives: This study was conducted to assess the safety and tolerability of TRTP‐101 in adults with atrophic scars. Methods: In this first‐in‐human, Phase I, single‐arm pilot study, adults (≥ 19 years) with atrophic scars meeting prespecified criteria underwent autologous adipose harvest from the abdomen and subsequent intradermal administration of TRTP‐101 (1 × 10 7 cells/mL; up to 0.2 mL per scar) into four target scars per participant. Safety was the primary endpoint. Exploratory efficacy was assessed using percentage change in depression volume measured by 3D image analysis at Weeks 1, 4, 8, 12, and 24, with follow‐up extending up to 1 year. Results: Three participants received TRTP‐101 and completed 1‐year follow‐up. No dose‐limiting toxicities, treatment‐related adverse events, or late‐onset reactions were observed throughout the follow‐up period. The mean percentage reductions in atrophic scar volume were 21.27%, 19.72%, 18.88%, and 26.60% at Weeks 1, 4, 8, and 12, respectively, with a mean reduction of 19.31% at 1 year. Conclusions: A single intradermal administration of TRTP‐101 was well tolerated throughout 1 year and showed early, quantifiable reductions in scar depression volume, with a mean reduction still observed at 1 year. This first‐in‐human study may provide preliminary support for the safety and potential regenerative role of autologous ADMSC‐derived 3D MiBs for atrophic scars and supports further controlled clinical evaluation. Trial Registration : ClinicalTrials.gov NCT06210919 (first posted January 18, 2024) and NCT06435884 (first posted May 30, 2024)

31 December 2025 in Journal of the Korean Society for Psoriasis
Verified
Journal Article
Open access
PDF file
JJJunesoo Jeon
Junesoo Jeon
SOSe Jin Oh
Se Jin Oh
Junesoo Jeon, Sejin Oh. Journal of the Korean Society for Psoriasis 2025;22:110-2. https://doi.org/10.23203/JKSP.2025.22.2.110

1 January 2026 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
SOSe Jin Oh
Se Jin Oh
JNJunghyun Namkung
Junghyun Namkung
JJJunesoo Jeon
Junesoo Jeon
YLYeonju Lee
Yeonju Lee
DYDokyoung Yoon
Dokyoung Yoon
JLJong Hee Lee
Jong Hee Lee
Oh S, et al. Ann Dermatol. 2026 ;38:e76. https://doi.org/10.5021/ad.26.119

1 January 2026 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
SOSe Jin Oh
Se Jin Oh
JSJoonho Shim
Joonho Shim
DYDokyoung Yoon
Dokyoung Yoon
HKHeeyeon Kim
Heeyeon Kim
JJJunesoo Jeon
Junesoo Jeon
JLJoo-Heung Lee
Joo-Heung Lee
Oh S, et al. Ann Dermatol. 2026 ;38:e79. https://doi.org/10.5021/ad.26.126

1 January 2026 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
JPJihye Park
Jihye Park
HJHyung-Suk Jang
Hyung-Suk Jang
JJJunesoo Jeon
Junesoo Jeon
MGMarta Gonçalves
Marta Gonçalves
SBSofia Brito
Sofia Brito
JLJong Hee Lee
Jong Hee Lee
Park J, et al. Ann Dermatol. 2026 ;38:e63. https://doi.org/10.5021/ad.26.069